Capitalize on New Indications, Improve Safety, Efficacy, Tolerability, & Adherence Through Alternative Delivery Methods & Combination Products
Welcome to the 3rd GLP-1 Based Therapeutics Summit – the essential industry forum dedicated to solving the critical challenges of GLP-1 combinations, mastering tolerability, drug delivery, and seizing the multi-billion dollar opportunity in non-obesity indications.
Driven by unprecedented clinical success, this revolutionary drug class has created multi-billion dollar franchises, but the market is now reaching a critical juncture where differentiation is everything. The pressure is on to move beyond monotherapy and unlock new levels of efficacy in areas like neuroscience and cardiorenal protection, promising unparalleled potential to conquer widespread chronic diseases.
The 3rd GLP-1 Based Therapeutics Summit stands as the global forum for experts dedicated to accelerating this vital progress. This year, we're diving deep into the game-changing potential of multi-agonist combinations, next-generation tolerability, and strategic commercial planning.
Hear from the titans of the pharmaceutical industry, including Eli Lilly, AstraZeneca, Merck, and Takeda, as well as innovative biotechs and financial institutions who will share their groundbreaking research and strategies for developing best-in-class treatments that transform patient lives.
Speakers were engaged and highly accessible, sharing novel and practical data. The discussions were interactive, and the workshops helpful. Big Pharma shared data and other ecosystem players engaged in productive dialogue.
Chief Therapeutics Officer, Eleven Therapeutics
Quality of the presentations was impressive - lots of new info and ideas. Excellent attendees and speakers.
Chief Executive Officer, Harvest Moon Pharmaceuticals
It was extremely useful to learn that we are at the beginning of the journey with GLP-1 will all the future possibilities in terms of therapeutic areas.
Chief Commercial Officer, Recipharm AB
Explore the Full Event Guide
- Analyze clinical strategies for reducing adverse GI effects and optimizing the side effect profile to improve patient comfort ensuring greater medication adherence
- Access advanced research and clinical insights on emerging multi-agonists (e.g., GLP-1/GCG/Amylin) and pharmacogenetics (PMX)
- Explore sessions dedicated to gaining the commercial and clinical blueprint for pioneering GLP-1 therapies in new frontiers
- Strategically apply collated insights from recent FDA-approved drugs and successful trial data
- Discover two focused, practical workshops that will provide actionable strategies on drug modelling and design
Expertise Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.